236 related articles for article (PubMed ID: 12751915)
1. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.
Nordmann AJ; Krahn M; Logan AG; Naglie G; Detsky AS
Pharmacoeconomics; 2003; 21(8):573-85. PubMed ID: 12751915
[TBL] [Abstract][Full Text] [Related]
2. A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
Anis AH; Sun H; Singh S; Woolcott J; Nosyk B; Brisson M
Pharmacoeconomics; 2006; 24(4):387-400. PubMed ID: 16605284
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
[TBL] [Abstract][Full Text] [Related]
4. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
5. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
Schmieder RE; Martus P; Klingbeil A
JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.
Wong FL; Bhatia S; Landier W; Francisco L; Leisenring W; Hudson MM; Armstrong GT; Mertens A; Stovall M; Robison LL; Lyman GH; Lipshultz SE; Armenian SH
Ann Intern Med; 2014 May; 160(10):672-83. PubMed ID: 24842414
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.
Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM
Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
Rosen AB; Hamel MB; Weinstein MC; Cutler DM; Fendrick AM; Vijan S
Ann Intern Med; 2005 Jul; 143(2):89-99. PubMed ID: 16027450
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
CDC Diabetes Cost-effectiveness Group
JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
[TBL] [Abstract][Full Text] [Related]
10. Patterns of prescription antihypertensive drug utilization and adherence to treatment guidelines in the city of Novi Sad.
Tomas A; Tomić Z; Milijasević B; Ban M; Horvat O; Vukmirović S; Sabo A
Vojnosanit Pregl; 2016 Jun; 73(6):531-7. PubMed ID: 27498444
[TBL] [Abstract][Full Text] [Related]
11. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure.
Siegel D; Lopez J
JAMA; 1997 Dec; 278(21):1745-8. PubMed ID: 9388150
[TBL] [Abstract][Full Text] [Related]
12. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996).
Schmieder RE; Schlaich MP; Klingbeil AU; Martus P
Nephrol Dial Transplant; 1998 Mar; 13(3):564-9. PubMed ID: 9550628
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.
Klingbeil AU; Schneider M; Martus P; Messerli FH; Schmieder RE
Am J Med; 2003 Jul; 115(1):41-6. PubMed ID: 12867233
[TBL] [Abstract][Full Text] [Related]
14. How well have practices followed guidelines in prescribing antihypertensive drugs: the role of health insurance.
Guo JD; Liu GG; Christensen DB; Fu AZ
Value Health; 2003; 6(1):18-28. PubMed ID: 12535235
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
16. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
Banka G; Heidenreich PA; Fonarow GC
J Am Coll Cardiol; 2013 Apr; 61(13):1440-6. PubMed ID: 23433562
[TBL] [Abstract][Full Text] [Related]
17. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
[TBL] [Abstract][Full Text] [Related]
18. [Antihypertensive pharmacotherapy of patients in primary care with either a statutory or private health insurance].
Laux G; Szecsenyi J; Miksch A; Grün B; Gutscher A; Grün B; Rosemann T; Kühlein T
Med Klin (Munich); 2009 Feb; 104(2):108-13. PubMed ID: 19242661
[TBL] [Abstract][Full Text] [Related]
19. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.
Taylor M; Scuffham PA; Chaplin S; Papo NL
Value Health; 2009 Jun; 12(4):459-65. PubMed ID: 19192258
[TBL] [Abstract][Full Text] [Related]
20. Economic impact of regression of left ventricular hypertrophy by antihypertensive drugs.
Eagle KA; Blank DJ; Aguiar E; Firth LM
J Hum Hypertens; 1993 Aug; 7(4):341-51. PubMed ID: 8105082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
